Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3U7SZ)

Drug Name
Romiplostim Drug Info
Indication
Disease Entry ICD 11 Status REF
Thrombocytopenia 3B64 Approved [1]
Multiple myeloma 2A83 Phase 2 [2]
Myelodysplastic syndrome 2A37 Phase 2 [1]
Cross-matching ID
PubChem CID
5329098
ChEBI ID
CHEMBL276711
CAS Number
CAS 194413-58-6
TTD Drug ID
DM3U7SZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Thrombopoietin receptor (MPL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eltrombopag DMOGFIX Thrombocytopenia 3B64 Approved [12]
Lusutrombopag DMH6IKO Thrombocytopenia 3B64 Approved [13]
AS-1670542 DMV05SW Thrombocytopenia 3B64 Approved [14]
LGD-4665 DM9T8A2 Immune thrombocytopenic purpura 3B64.13 Phase 2 [12]
BVI-007 DM43GPX Myocardial infarction BA41-BA43 Phase 1 [14]
NIP-004 DM0PYEQ Thrombocytopenia 3B64 Phase 1 [15]
RhTPO DMCV0BZ Idiopathic thrombocytopenic purpura 3B64.10 Discontinued in Phase 3 [12]
Totrombopag DM6SUDC Thrombocytopenia 3B64 Discontinued in Phase 1 [16]
Promegapoietin DMS4FG0 Bone marrow transplantation QB63.6 Terminated [17]
N. A. N. A. [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aryl hydrocarbon receptor (AHR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tapinarof DMRPI2Q Plaque psoriasis EA90.0 Approved [18]
RVT-505 DM3C9F8 Atopic dermatitis EA80 Phase 2 [19]
IK-175 DMDU54Y Urothelial carcinoma 2C92.0 Phase 1 [20]
BAY 2416964 DMD9N12 Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
AT-177 DMJ02RH Ulcerative colitis DD71 Clinical trial [22]
CB7993113 DMJUQ6E Solid tumour/cancer 2A00-2F9Z Preclinical [23]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester DMIS1G7 Glioma 2A00.0 Preclinical [24]
6-Formylindolo[3,2-b]carbazole DMN84RM Dermatitis EA80-EA89 Investigative [25]
CH-223191 DMMJZYC Solid tumour/cancer 2A00-2F9Z Investigative [26]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [27]
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [28]
Infigratinib DMNKBEC Cholangiocarcinoma 2C12.10 Approved [29]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [30]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [31]
ARQ-087 DM02BVQ Intrahepatic cholangiocarcinoma 2C12.10 Phase 3 [32]
AZD4547 DM3827C Solid tumour/cancer 2A00-2F9Z Phase 2/3 [33]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [34]
AM-001 DMGVQI8 Actinic keratosis EK90.0 Phase 2 [35]
FGF-1 DMXMC8I Coronary heart disease BA80.Z Phase 2 [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [37]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [38]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [39]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [30]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [40]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [41]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [42]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [43]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [44]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [46]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [47]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [48]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [48]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [49]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [50]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [37]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [41]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [42]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [47]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [17]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [30]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [41]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [42]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [51]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [52]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [53]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [45]
PMID25656651-Compound-21a DMCKAON N. A. N. A. Patented [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Ret (RET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [48]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [48]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [46]
Selpercatinib DMZR15V Non-small-cell lung cancer 2C25.Y Approved [55]
Pralsetinib DMWU0I2 Non-small-cell lung cancer 2C25.Y Approved [56]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [57]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [34]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [58]
GSK3179106 DM2KCIP Inflammatory bowel disease DD72 Phase 1 [59]
BOS172738 DM9L0D8 Solid tumour/cancer 2A00-2F9Z Phase 1 [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting VEGFR1 messenger RNA (VEGFR1 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VATALANIB DMY0UEQ Solid tumour/cancer 2A00-2F9Z Phase 2 [61]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [51]
Sirna-027 DMZTQD8 Exudative age-related macular degeneration 9B78.3Z Phase 1/2 [62]
PMID22765894C8h DMH5RFU Discovery agent N.A. Investigative [63]
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 Discovery agent N.A. Investigative [64]
AAL-993 DM35RFH Discovery agent N.A. Investigative [61]
PMID17935989C25 DML8ZBR Discovery agent N.A. Investigative [65]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT Discovery agent N.A. Investigative [66]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 Discovery agent N.A. Investigative [67]
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMQWD75 Discovery agent N.A. Investigative [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [47]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [48]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [68]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [69]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [46]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [49]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [70]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [71]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [72]
Lenvatinib DMB1IU4 Thyroid cancer 2D10 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Receptor-type tyrosine-protein kinase FLT3 (FLT3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [74]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [75]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [76]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [77]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [78]
Venetoclax DM8I94Y Chronic lymphocytic leukaemia 2A82.0 Approved [79]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [80]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [81]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [82]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [83]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Gasdermin-D (GSDMD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [84]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [85]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [86]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [87]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [88]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [89]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [9]
Ropivacaine DMSPJG2 Anaesthesia 9A78.6 Approved [90]
Paclitaxel DMLB81S Breast carcinoma Approved [91]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [92]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aryl hydrocarbon receptor (AHR) TT037IE AHR_HUMAN Modulator [3]
Fibroblast growth factor receptor 1 (FGFR1) TTRLW2X FGFR1_HUMAN Inhibitor [4]
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [5]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [5]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [6]
Thrombopoietin receptor (MPL) TTIHYA4 TPOR_HUMAN Modulator [7]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [8]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [4]
VEGFR1 messenger RNA (VEGFR1 mRNA) TT1VAUK VGFR1_HUMAN Inhibitor [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Gene/Protein Processing [9]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Gene/Protein Processing [10]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Gene/Protein Processing [11]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
3 A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
4 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
5 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
6 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
7 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
9 Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
10 SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1;102(3):795-801. doi: 10.1182/blood-2002-10-3023. Epub 2003 Mar 20.
11 SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
12 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
13 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
15 A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
16 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Clinical pipeline report, company report or official report of Ikena Oncology.
21 ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
22 Clinical pipeline report, company report or official report of Azora Therapeutics
23 In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
24 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
25 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
26 Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
27 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
28 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
29 Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
30 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
31 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
33 AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
34 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
36 Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
37 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
38 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
39 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
40 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
41 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
42 National Cancer Institute Drug Dictionary (drug id 452042).
43 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
44 Clinical pipeline report, company report or official report of MedImmune (2011).
45 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
46 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
47 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
49 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
50 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
51 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
52 Company report (Neuronova)
53 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
54 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
55 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
56 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
58 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
59 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
60 National Cancer Institute Drug Dictionary (drug name Zeteletinib).
61 Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
62 2011 Pipeline of Sirna Therapeutics.
63 The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
64 Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
65 Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
66 Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
67 Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
68 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
69 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
70 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
71 Clinical pipeline report, company report or official report of Exelixis (2011).
72 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
73 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
74 Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
75 Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28.
76 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
77 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
78 Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006 Nov 15;12(22):6817-25. doi: 10.1158/1078-0432.CCR-06-1354.
79 HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2023 Aug 23;45(9):7011-7026. doi: 10.3390/cimb45090443.
80 Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.
81 Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.
82 Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
83 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
84 CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
85 Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
86 Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm Res. 2021 May;70(5):543-552. doi: 10.1007/s00011-021-01457-y. Epub 2021 Apr 13.
87 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
88 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
89 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
90 Dexmedetomidine protects against Ropivacaine-induced neuronal pyroptosis via the Nrf2/HO-1 pathway. J Toxicol Sci. 2023;48(3):139-148. doi: 10.2131/jts.48.139.
91 The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
92 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.